Bristol-Myers Squibb

Alabama settles suits against 5 drug companies

San Fransisco Chronicle (Free subscription) | yesterday

The state of Alabama has settled Medicaid drug pricing lawsuits it filed against drugmaker Bristol-Myers Squibb and four other companies. A lawyer representing the state, Jere Beasley, confirmed Friday the settlement has been reached. Bristol-Myers Squibb is...

• Alabama settles suits against 5 drug companies - kansascity.com
• Alabama settles suits against 5 drug companies - Seattle Post-Intelligencer

Alabama settles suits against 5 drug companies

Seattle Times (Free subscription) | yesterday

The state of Alabama has settled Medicaid drug pricing lawsuits it filed against drugmaker Bristol-Myers Squibb and four other companies.

Alabama settles suits against 5 drug companies

The Washington Times (Free subscription) | yesterday

The state of Alabama has settled Medicaid drug pricing lawsuits it filed against drugmaker Bristol-Myers Squibb and four other companies.

4-Star Stocks Poised to Pop: Bristol-Myers Squibb

Fool.com (Free subscription) | 10/08/2008

Market-trouncing returns could be written in these four stars.

Lilly To Pay Big For ImClone

Chemical and Engineering News (Free subscription) | 10/08/2008

$6.5 billion bid trumps offer from Bristol-Myers Squibb

FDA Approved Use Of REYATAZ (R) Boosted With Ritonavir, In Combination Therapy, For Previously Untreated HIV-1 Infected Adult Patients

Medical News Today (Free subscription) | 10/08/2008

Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food & Drug Administration (FDA) approved the use of REYATAZ® (atazanavir sulfate) 300 mg once-daily boosted with ritonavir 100 mg as part of combination therapy in previously untreated (treatment-naive) HIV-1 infected patients. REYATAZ boosted with ritonavir (REYATAZ/r) taken once daily with food is recognized by the U.S.

Biotech Stocks: Bristol-Myers, Lilly lead drug stocks rebound

Market Watch (Free subscription) | 10/07/2008

Bristol-Myers Squibb and Eli Lilly & Co. led a rebound in drug stock issues early Tuesday, the day after the sector was battered by a massive global sell-off.

Bristol-Myers, Lilly lead rebound in drug stocks

Market Watch (Free subscription) | 10/07/2008

BOSTON (MarketWatch) -- Bristol-Myers Squibb and Eli Lilly & Co. led a rebound in drug stock issues early Tuesday, the day after the sector was battered by a massive global sell-off. The Amex Pharmaceutical Index rose 1.7% to 282.93 and the Amex Biotechnology Index advanced 1% to 705.76. Shares of Bristol-Myers and Lilly both jumped about 3% in early action. On Monday, Lilly announced it has signed...

Eli Lilly to Pay $6.5 Billion to Buy ImClone

Red Orbit (Free subscription) | 10/07/2008

By Julie Schmit Drugmaker Eli Lilly agreed Monday to pay $6.5 billion for biotech-drug maker ImClone Systems, beating an offer by Bristol-Myers Squibb and boosting its stable of cancer drugs.

Eli Lilly ties dovetail for another deal

Indy Star (Free subscription) | 10/07/2008

When Eli Lilly and Co. made its bid for biotech drug developer ImClone Monday, it looked like Bristol-Myers Squibb Chairman Jim Cornelius was about to get into another bidding war.

Lilly agrees to take over ImClone

Financial Time (Free subscription) | 10/07/2008

Eli Lilly has agreed to take over ImClone, the biotech company controlled by Carl Icahn, for $6.5bn or $70 per share, trumping a hostile bid from Bristol-Myers Squibb...

Lilly to Buy ImClone for $6.5 Billion

New York Times (Free subscription) | 10/06/2008

The bid by Lilly for the biotechnology company beat out an offer from Bristol-Myers Squibb, which markets ImClone’s cancer drug Erbitux in the United States along with ImClone.

Eli Lilly to buy ImClone for more than $6B

The Washington Times (Free subscription) | 10/06/2008

Eli Lilly & Co. has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm ImClone Systems Inc. in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co.

Bristol-Myers won't raise bid for ImClone

Market Watch (Free subscription) | 10/06/2008

BOSTON (MarketWatch) -- Bristol-Myers Squibb said Monday that it will not raise its $62 as share bid for ImClone Systems , in which it already holds a 16.6% stake, adding that raising the bid was not in the best interest of its shareholders. Earlier Monday, Eli Lilly & Co. announced that it plans to buy ImClone for $70 a share, or $6.5 billion, in an effort to expand its presence in the oncology market....

Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner

Business Wire (Free subscription) | 10/06/2008

PRINCETON, N.J.--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) announced today that it will acquire ImClone Systems (NASDAQ:IMCL) for $70 per share, or approximately $6.5 billion.